Potential therapeutic effects of pigment epithelium-derived factor for treatment of diabetic retinopathy

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 221-227

  Liu, Xiao ^a   Chen, Hui Hui ^a   Zhang, Li Wei ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Diabetic retinopathy; Molecular therapeutics; Pigment epithelium derived factor; Pleiotropic functions

Indexed keywords

EID: 84894556832     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/J.ISSN.2222-3959.2013.02.22     Document Type: Review

References (69)

1. Fong DS, Aiello L, Gardner T.W., King GL, Blankenship G, Cavallerano JD, Ferris III FL, Klein R. Retinopathy in diabetes. Diabetes Care. 2004; 27(1): 84-87.
2. Yang SH, Dou KF, Song WJ. Prevalence of diabetes among men and women in China. N Engl J Med. 2010; 362(25): 2425-2426.
3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007; 298(8): 902-916.
4. Becerra SP. Focus on molecules: pigment epithelium-derived factor (PEDF) Exp Eye Res. 2006; 82(5): 739-740.
5. Filleur S, Nelius T, de Riese W, Kennedy RC. Characterization of PEDF: a multi-functional serpin family protein. J Cell Biochem. 2009; 106(5): 769-775.
6. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci. 2005; 10: 2131-2149.
7. Kawaguchi T, Yamagishi SI, Sata M. Structure-function relationships of PEDF. Curr Mol Med. 2010; 10(3): 302-311.
8. Tombran-Tink J., Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989; 30(8): 1700-1707.
9. Tombran-Tink J., Chader GG, Johnson LV. PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991; 53(3): 411-414.
10. Ogata N, Matsuoka M, Matsuyama K., Shima C, Tajika A, Nishiyama T., Wada M, Jo N, Higuchi A., Minamino K, Matsunaga H, Takeda T., Matsumura M. Plasma concentration of pigment epithelium-derived factor in patients with diabetic retinopathy. J Clin Endocrinol Metab. 2007; 92(3): 1176-1179.
11. Zheng B, Li T, Chen H., Xu X, Zheng Z. Correlation between Ficolin-3 and vascular endothelial growth factor-to-pigment epithelium-derived factor ratio in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol. 2011; 152(6): 1039-1043.
12. Yoshida Y, Yamagishi S, Matsui T., Nakamura K, Imaizumi T, Yoshimura K., Yamakawa R. Positive correlation of pigment epithelium-derived factor and total antioxidant capacity in aqueous humour of patients with uveitis and proliferative diabetic retinopathy. Br J Ophthalmol. 2007; 91(9): 1133-1134.
13. Funatsu H, Noma H, Mimura T., Eguchi S, Hori S. Association of vitreous inflammatory factors with diabetic macular edema. Ophthalmology. 2009; 116(1): 73-79.
14. Ogata N, Nishikawa M, Nishimura T., Mitsuma Y, Matsumura M. Unbalanced vitreous levels of pigment epithelium-derived factor and vascular endothelial growth factor in diabetic retinopathy. Am J Ophthalmol. 2002; 134(3): 348-353.
15. Nam DH, Oh J, Roh J.H., Huh K. Different expression of vascular endothelial growth factor and pigment epithelium-derived factor between diabetic and non-diabetic epiretinal membranes. Ophthalmologica. 2009; 223(3): 188-191.
16. Yamagishi S, Adachi H, Abe A., Yashiro T, Enomoto M, Furuki K., Hino A, Jinnouchi Y, Takenaka K., Matsui T, Nakamura K, Imaizumi T. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab. 2006; 91(6): 2447-2450.
17. Haurigot V, Villacampa P, Ribera A., Bosch A, Ramos D, Ruberte J., Bosch F. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy. PLoS One. 2012; 7(7): e41511.
18. Longeras R, Farjo K, Ihnat M., Ma JX. A PEDF-derived peptide inhibits retinal neovascularization and blocks mobilization of bone marrow-derived endothelial progenitor cells. Exp Diabetes Res. 2012; 2012: 518426.
19. Barber AJ, Gardner TW, Abcouwer SF. The significance of vascular and neural apoptosis to the pathology of diabetic retinopathy. Invest Ophthalmol Vis Sci. 2011; 52(2): 1156-1163.
20. Lange J, Yafai Y, Reichenbach A., Wiedemann P, Eichler W. Regulation of pigment epithelium-derived factor production and release by retinal glial (Müller) cells under hypoxia. Invest Ophthalmol Vis Sci. 2008; 49(11): 5161-5167.
21. Yoshida Y, Yamagishi S, Matsui T., Jinnouchi Y, Fukami K, Imaizumi T., Yamakawa R. Protective role of pigment epithelium-derived factor (PEDF) in early phase of experimental diabetic retinopathy. Diabetes Metab Res Rev. 2009; 25(7): 678-686.
22. Barnstable CJ, Tombran-Tink J. Neuroprotective and antiangiogenic action of PEDF in the eye: molecular targets and therapeutic potential. Prog Retin Eye Res. 2004; 23(5): 561-577.
23. Villarroel M, Ciudin A, Hernández C, Simó R. Neurodegeneration: an early event of diabetic retinopathy. World J Diabetes. 2010; 1(2): 57-64.
24. Shaked I, Ben-Dror I, Vardimon L. Glutamine synthetase enhances the clearance of extracelluar glutamate by the neural retina. J Neurochem. 2002; 83(3): 574-580.
25. Shen X, Zhong Y, Xie B., Cheng Y, Jiao Q. Pigment epithelium derived factor as an anti-inflammatory factor against decrease of glutamine synthetase expression in retinal Müller cells under high glucose conditions. Graefes Arch Clin Exp Ophthalmol. 2010; 248(8): 1127-1136.
26. Shen X, Xie B, Cheng Y., Jiao Q, Zhong Y. Effect of pigment epithelium derived factor on the expression of glutamine synthetase in early phase of experimental diabetic retinopathy. Ocul Immunol Inflamm. 2011; 19(4): 246-254.
27. Li Q, Puro DG. Diabetes-induced dysfunction of the glutamate transporter in retina. Invest Ophthalmol Vis Sci. 2002; 43(9): 3109-3116.
28. Xie B, Jiao Q, Cheng Y., Zhong Y, Shen X. Effect of pigment epithelium-derived factor on glutamate uptake in retinal Müller cells under high-glucose conditions. Invest Ophthalmol Vis Sci. 2012; 53(2): 1023-1032.
29. Motiejunaite R, Kazlauskas A. Pericytes and ocular diseases. Exp Eye Res. 2008; 86(2): 171-177.
30. Yamagishi S, Inagaki Y, Amano S., Okamoto T, Takeuchi M, Makita Z. Pigment epithelium-derived factor protects cultured retinal pericytes from advanced glycation end product-induced injury through its antioxidative properties. Biochem Biophys Res Commun. 2002; 296(4): 877-882.
31. Sheikpranbabu S, Haribalaganesh R, Gurunathan S. Pigment epithelium-derived factor inhibits advanced glycation end-products-induced cytotoxicity in retinal pericytes. Diabetes Metab. 2011; 37(6): 505-511.
32. Haribalaganesh R, Sheikpranbabu S, Elayappan B., Venkataraman D, Gurunathan S. Pigment-epithelium-derived factor down regulates hyperglycemia-induced apoptosis via PI3K/Akt activation in goat retinal pericytes. Angiogenesis. 2009; 12(4): 381-389.
33. Amano S, Yamagishi S, Inagaki Y., Nakamura K, Takeuchi M, Inoue H., Imaizumi T. Pigment epithelium-derived factor inhibits oxidative stress-induced apoptosis and dysfunction of cultured retinal pericytes. Microvasc Res. 2005; 69(1-2): 45-55.
34. Yamagishi S, Nakamura K, Ueda S., Kato S, Imaizumi T. Pigment epithelium-derived factor (PEDF) blocks angiotensin II signaling in endothelial cells via suppression of NADPH oxidase: a novel anti-oxidative mechanism of PEDF. Cell Tissue Res. 2005; 320(3): 437-445.
35. Yamagishi S, Matsui T. Advanced glycation end products (AGEs), oxidative stress and diabetic retinopathy. Curr Pharm Biotechnol. 2011; 12(3): 362-368.
36. Yamagishi S, Matsui T, Nakamura K., Yoshida T, Takeuchi M, Inoue H., Yoshida Y, Imaizumi T. Pigment-epithelium-derived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res. 2007; 39(2): 92-97.
37. Ueda S, Yamagishi SI, Okuda S. Anti-vasopermeability effects of PEDF in retinal-renal disorders. Curr Mol Med. 2010; 10(3): 279-283.
38. Yamagishi S, Abe R, Jinnouchi Y., Matsui T, Imaizumi T, Inoue H. Pigment epithelium-derived factor inhibits vascular endothelial growth factor-induced vascular hyperpermeability both in vitro and in vivo. J Int Med Res. 2007; 35(6): 896-899.
39. Yamagishi S, Nakamura K, Matsui T., Inagaki Y, Takenaka K, Jinnouchi Y., Yoshida Y, Matsuura T, Narama I., Motomiya Y, Takeuchi M, Inoue H., Yoshimura A, Bucala R, Imaizumi T. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem. 2006; 281(29): 20213-20220.
40. Liu H, Ren JG, Cooper W.L., Hawkins CE, Cowan MR, Tong PY. Identification of the antivasopermeability effect of pigment epithelium-derived factor and its active site. Proc Natl Acad Sci USA. 2004; 101(17): 6605-6610.
41. Zhang SX, Wang JJ, Gao G, Shao C., Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J. 2006; 20(2): 323-325.
42. Wallez Y, Huber P. Endothelial adherens and tight junctions in vascular homeostasis, inflammation and angiogenesis. Biochim Biophys Acta. 2008; 1778(3): 794-809.
43. Wu D, Pan W. GSK3: a multifaceted kinase in Wnt signaling. Trends Biochem Sci. 2010; 35(3): 161-168.
44. El-Remessy A.B., Behzadian MA, Abou-Mohamed G, Franklin T., Caldwell RW, Caldwell RB. Experimental diabetes causes breakdown of the blood-retina barrier by a mechanism involving tyrosine nitration and increases in expression of vascular endothelial growth factor and urokinase plasminogen activator receptor. Am J Pathol. 2003; 162(6): 1995-2004.
45. Navaratna D, Menicucci G, Maestas J., Srinivasan R, McGuire P, Das A. A peptide inhibitor of the urokinase/urokinase receptor system inhibits alteration of the blood-retinal barrier in diabetes. FASEB J. 2008; 22(9): 3310-3317.
46. Behzadian MA, Windsor LJ, Ghaly N, Liou G., Tsai NT, Caldwell RB. VEGF-induced paracellular permeability in cultured endothelial cells involves urokinase and its receptor. FASEB J. 2003; 17(6): 752-754.
47. Yang J, Duh EJ, Caldwell R.B., Behzadian MA. Antipermeability function of PEDF involves blockade of the MA P kinase/GSK/beta-catenin signaling pathway and uPAR expression. Invest Ophthalmol Vis Sci. 2010; 51(6): 3273-3280.
48. Cai J, Wu L, Qi X., Li Calzi S, Caballero S, Shaw L., Ruan Q, Grant MB, Boulton ME. PEDF regulates vascular permeability by a γ-secretase-mediated pathway. PLoS One. 2011; 6(6): e211164.
49. Chibber R, Ben-Mahmud BM, Chibber S., Kohner EM. Leukocytes in diabetic retinopathy. Curr Diabetes Rev. 2007; 3(1): 3-14.
50. Patel N. Targeting leukostasis for the treatment of early diabetic retinopathy. Cardiovasc Hematol Disord Drug Targets. 2009; 9(3): 222-229.
51. Matsuoka M, Ogata N, Minamino K., Matsumura M. Leukostasis and pigment epithelium-derived factor in rat models of diabetic retinopathy. Mol Vis. 2007; 13: 1058-1065.
52. Yamagishi S, Matsui T, Nakamura K., Takeuchi M, Imaizumi T. Pigment epithelium-derivedfactor (PEDF) prevents diabetes- or advanced glycation end products (AGE)-elicited retinal leukostasis. Microvasc Res. 2006; 72(1-2): 86-90.
53. Issbrücker K., Marti HH, Hippenstiel S, Springmann G., Voswinckel R, Gaumann A, Breier G., Drexler HC, Suttorp N, Clauss M. p38 MAP kinase - a molecular switch between VEGF-induced angiogenesis and vascular hyperpermeability. FASEB J. 2003; 17(2): 262-264.
54. Breslin JW, Pappas PJ, Cerveira J.J., Hobson RW, Durán WN. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol. 2003; 284(1): H92-H100.
55. Zhang SX, Wang JJ, Gao G, Parke K., Ma JX. Pigment epithelium-derived factor downregulates vascular endothelial growth factor (VEGF) expression and inhibits VEGF-VEGF receptor 2 binding in diabetic retinopathy. J Mol Endocrinol. 2006; 37(1): 1-12.
56. Cai J, Jiang WG, Grant M.B., Boulton M. Pigment epithelium-derived factor inhibits angiogenesis via regulated intracellular proteolysis of vascular endothelial growth factor receptor 1. J Biol Chem. 2006; 281(6): 3604-3613.
57. Chen Y, Hu Y, Lu K., Flannery JG, Ma JX. Very low density lipoprotein receptor, a negative regulator of the wnt signaling pathway and choroidal neovascularization. J Biol Chem. 2007; 282(47): 34420-34428.
58. Park K, Lee K, Zhang B., Zhou T, He X, Gao G., Murray AR, Ma JX. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol. 2011; 31(14): 3038-3051.
59. Wong WT, Rex TS, Auricchio A, Maguire A.M., Chung D., Tang W, Bennett J. Effect of over-expression of pigment epithelium derived factor (PEDF) on developing retinal vasculature in the mouse. Mol Vis. 2004; 10: 837-844.
60. Campochiaro PS, Nguyen QD, Shah S.M., Klein ML, Holz E, Frank RN, Saperstein D.A., Gupta A., Stout JT, Macko J, Di Bartolomeo R, Wei LL. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther. 2006; 17(2): 167-176.
61. Stellmach V, Crawford SE, Zhou W, Bouck N. Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Sci USA. 2001; 98(5): 2593-2597.
62. Amaral J, Becerra SP. Effects of human recombinant PEDF protein and PEDF-derived peptide 34-mer on choroidal neovascularization. Invest Ophthalmol Vis Sci. 2010; 51(3): 1318-1326.
63. Bernard A, Gao-Li J, Franco C.A., Bouceba T., Huet A, Li A. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem. 2009; 284(16): 10480-10490.
64. Mirochnik Y, Aurora A, Schulze-Hoepfner FT, Deabes A., Shifrin V, Beckmann R, Polsky C., Volpert OV. Short pigment epithelial-derived factor-derived peptide inhibits angiogenesis and tumor growth. Clin Cancer Res. 2009; 15(5): 1655-1663.
65. Filleur S, Volz K, Nelius T., Mirochnik Y, Huang H, Zaichuk T.A., Aymerich MA, Becerra SP, Yap R, Veliceasa D., Shroff EH, Volpert OV. Two functional epitopes of pigment epithelial-derived factor block angiogenesis and induce differentiation in prostate cancer. Cancer Res. 2005; 65(12): 5144-5152.
66. Li H, Tran VV, Hu Y, Mark Saltzman W, Barnstable CJ, Tombran-Tink J. A PEDF N-terminal peptide protects the retina from ischemic injury when delivered in PLGA nanospheres. Exp Eye Res. 2006; 83(4): 824-833.
67. Alberdi E, Aymerich MS, Becerra SP. Binding of pigment epithelium-derived factor (PEDF) to retinoblastoma cells and cerebellar granule neurons. Evidence for a PEDF receptor. J Biol Chem. 1999; 274(44): 31605-31612.
68. Park K, Jin J, Hu Y., Zhou K, Ma JX. Overexpression of pigment epithelium-derived factor inhibits retinal inflammation and neovascularization. Am J Pathol. 2011; 178(2): 688-698.
69. Bai YJ, Huang LZ, Xu X.L., Du W., Zhou AY, Yu WZ, Li XX. Polyethylene glycol-modified pigment epithelial-derived factor: new prospects for treatment of retinal neovascularization. J Pharmacol Exp Ther. 2012; 342(1): 131-139.